The Safety and Efficacy of Sequential Hormone Therapy and IBI311 Therapy in Patients With Active Moderate to Severe TAO in the Initial Treatment.

Launched by ·

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment for people with moderate to severe thyroid-associated ophthalmopathy (TAO), a condition linked to thyroid disease that affects the eyes. TAO can cause eye swelling, pain, and in serious cases, vision problems or even blindness. The trial is testing a medicine called IBI311, which is designed to block certain signals that cause harmful changes in the eye tissues. Researchers want to see how well IBI311 works compared to the usual treatment with hormone therapy, and to make sure it is safe for patients.

People eligible for this study are adults with active moderate to severe TAO who are starting treatment for the condition. If you join the trial, you will receive either the new IBI311 treatment or the standard hormone therapy, and the doctors will carefully monitor your response and any side effects. This study aims to find better treatment options to help protect eyesight and improve quality of life for people living with TAO.

Gender

ALL

Eligibility criteria